Wheeler Bio Expands with ATUM’s miFuc™ Platform for Enhanced Antibody Production

• Wheeler Bio has licensed ATUM’s miFuc™ platform to enhance its capabilities in producing afucosylated antibodies.

• The integration supports Wheeler Bio’s Portable CMC® platform, offering advanced CDMO services for antibody therapeutics.

Wheeler Bio, a contract development and manufacturing organisation (CDMO), has announced a strategic expansion by licensing ATUM’s miFuc™ platform. The technology enables the production of recombinant proteins, particularly afucosylated antibodies, that offer improved therapeutic windows and increased antibody-dependent cellular cytotoxicity (ADCC).

The partnership will allow Wheeler Bio to integrate miFuc™ into its Portable CMC® platform, a process that combines state-of-the-art equipment with rapid CHO pool generation, single clone isolation, and validation. This platform helps efficiently move candidates from cell line development through to CGMP clinical manufacturing.

The miFuc™ technology, enabled by ATUM’s Leap-In Transposase® system, enhances antibody efficacy by significantly reducing fucosylation without compromising cellular growth rates or protein titer. This advancement will allow Wheeler Bio’s clients to produce therapeutics with improved safety and efficacy profiles.

Jesse McCool, CEO & Co-Founder of Wheeler Bio, said: “With ATUM’s miFuc™ technology now integrated with our Portable CMC® platform, our clients have more flexibility for pharmaceutical development without risking timelines or scalability.”